TregTherapeutics Taps Eva Garland Consulting to Power Non-Dilutive Funding Strategy
Treg Therapeutics, a biotech developing therapies designed to restore immune tolerance, has announced a partnership with Eva Garland Consulting (EGC) to strengthen its non-dilutive funding strategy. The company is advancing its autoimmune tolerance platform and development programs, aiming for therapies that can restore immune tolerance rather than simply suppress the immune system. “For an emerging […]